Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 12/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3748474 | 1.00 | OPRL1 (0.48) | OPRL1OPRM1OPRK1ENPP2CACNA1G | |
| SCHEMBL3748046 | 0.89 | C5AR1 (0.52) | CACNA1GCACNA1HCYP3A4CYP2D6C5AR1 | |
| SCHEMBL3639898 | 0.89 | C5AR1 (0.52) | CACNA1GCACNA1HCYP3A4CYP2D6C5AR1 | |
| SCHEMBL13980437 | 0.85 | CYP3A4 (0.47) | OPRL1OPRM1CACNA1GCACNA1HCYP3A4 | |
| SCHEMBL3637418 | 0.85 | CYP3A4 (0.47) | OPRL1OPRM1CACNA1GCACNA1HCYP3A4 | |
| SCHEMBL3741812 | 0.85 | CACNA1G (0.53) | OPRL1OPRM1CACNA1GCACNA1HCYP3A4 | |
| SCHEMBL3669342 | 0.85 | CACNA1G (0.53) | OPRL1OPRM1CACNA1GCACNA1HCYP3A4 | |
| SCHEMBL13985802 | 0.84 | OPRL1 (0.48) | OPRL1OPRM1OPRK1ENPP2CACNA1G | |
| SCHEMBL3758795 | 0.84 | CHRM2 (0.40) | CACNA1GCACNA1HCYP3A4CYP2D6C5AR1 | |
| SCHEMBL3749221 | 0.84 | CHRM2 (0.40) | CACNA1GCACNA1HCYP3A4CYP2D6C5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-11-18 | — | — | US | claimed |
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-11-18 | — | — | US | disclosed |
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-11-18 | — | — | US | disclosed |
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-11-18 | — | — | US | disclosed |
| EP-1997805-A1 | Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans | Commissariat à l'Energie Atomique (FR) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997805-A1 | Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans | Commissariat à l'Energie Atomique (FR) | 2008-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | ABCB11, TPP1, ABCB1 | OPRL1 4337/4885OPRM1 4585/4885OPRK1 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.